Competitor beats Lilly to market with migraine drug approval
The competition for the multi-billion dollar migraine market is set to heat up with the FDA expected to decide on Lilly’s migraine therapy next month.
Health Care Businesses
Articles
Hc1.com dives deeper into opioid data, precision care
The Indianapolis medical-software firm recently raised $10 million in venture funding and is launching two major products in one month.
Lilly’s Elanco spinoff expected to raise up to $1.45 billion in IPO
The Greenfield-based animal health unit is gearing up for independence after 65 years as part of drugmaker Eli Lilly and Co. But Elanco has been struggling, and top management will have to work hard to stabilize the operation.
Q&A: What’s behind the growing scrutiny of insulin prices?
The American Medical Association recently called on regulators to monitor competition among the three drugmakers who control the market—Indianapolis-based Eli Lilly and Co., Denmark-based Novo Nordisk and Paris-based Sanofi.
China cuts red tape, increases potential for breakthrough medicines
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
Eli Lilly’s animal-health business files for initial public offering
Elanco Animal Health Inc. could see a market value of as much as $20 billion, according to Bloomberg Intelligence. At that valuation, a share sale could raise as much as $5 billion.
Firm crusades for insurers to cover alternative therapies
Carmel-based American Specialty Health specializes in connecting patients with chiropractors, acupuncturists, physical therapists and others who treat pain without using pharmaceutical drugs.
Lilly shares hit highest point in 18 years after Elanco decision
The run-up in share price seems to reflect investor sentiment that the Indianapolis drugmaker has turned a corner after more than a decade of struggling to launch new medicines.
Fraud scheme’s ‘CFO’ gets 5 years in prison; lesser player gets 4 months
Steven Ganote, who prosecutors say was a key player in the massive American Senior Communities overbilling and kickback scheme, was also ordered to pay $7 million in restitution.
Lilly unveils new $75M research building in Indianapolis
The pharmaceutical company said the 130,000-square-foot building will allow scientists to collaborate better on research for small molecules and synthetic peptides.
Prosecutors want 12-1/2-year sentence for nursing home exec involved in kickback scheme
James Burkhart, who pleaded guilty to fraud, will be sentenced June 27 in federal court. His lawyers are asking for a four-year sentence.
Startup raises $2.5M to launch medication-reminder tech product
Concordance Health Solutions’ Smart Med Reminder system reminds patients to take their meds and alerts caregivers or providers when an intervention is needed.
Health care research company terminating 98 workers in Indianapolis
In a letter to the Indiana Department of Workforce Development, the company said “changing business needs require us to reduce operations at this facility.”
In setback for Lilly, FDA limits dosage, slaps warning on new arthritis drug
The Indianapolis-based drugmaker has been working for years to develop the much-anticipated drug, which some analysts had said might ring up $2 billion a year in sales.
Trump unveils ‘sweeping’ plan to reduce prescription drug prices
President Donald Trump's long-awaited plan to bring down drug prices, unveiled Friday, will mostly spare the pharmaceutical industry he previously accused of "getting away with murder" and instead focus on increasing private competition.
IU organ researcher lands $9M grant to study animal transplants
The money is designed to further the work of Dr. Burcin Ekser and his team, who are working to print three-dimensional pig liver tissue from genetically engineered pig liver cells.
Major health initiative targets 3 Indianapolis neighborhoods with high diabetes rates
A five-year, $7 million program is led and supported by a coalition of local health institutions, including Eli Lilly and Co., Fairbanks School of Public Health and Eskenazi Health. It is based on a model that Lilly has used in other countries.
Eli Lilly’s next big push likely to come in pain treatments
The Indianapolis-based drugmaker has several pain medications in the pipeline, including potential treatments for migraine headaches, arthritis and chronic back pain.
Eli Lilly hikes forecast after better-than-expected first quarter
Indianapolis-based Eli Lilly and Co. on Tuesday reported quarterly revenue and adjusted earnings that exceeded analyst forecasts.
Drug industry sets lobbying records as pricing pressure looms
The drug industry set several quarterly records for lobbying spending in the first three months of 2018, but Indianapolis-based Eli Lilly and Co. actually reduced lobbying expenditures.